FIG. 1A




FIG. 1B

EVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY
CVKVGKDAKSDYRGQGTLVTVSSASIEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQ
PENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
(MW=77,984 daltons)

dAb
Linker
Modified IgG1 Fc from Abatacept (Cys→Ser, Pro→Ser)

FIG. 2




Cohort A: 75 mg N=10
Cohort B: 225 mg N=10
Cohort C : 675 mg mg N=10
Cohort D: 1500 mg N=10
Dose escalation
Dose escalation
Dose escalation
+
-
+
-
+
-
75 mg N=10
225 mg N=10
675 mg N=10
1500 mg N=10
FU
FU
FU
FU
Dosing every 2 weeks
Dosing every 2 weeks
Dosing every 2 weeks
Dosing every 2 weeks
6 week treatment phase (Response Phase)
6 week treatment phase (Remission Phase)
4 week follow up phase

FIG. 3


Intra-Subject Dose Escalation
75 mg N=10
6 weeks treatment phase
(PLT < 50,000)
Dose Escalate
225 mg N=10
6 weeks treatment phase
PLT response
PLT ≥ 50,000
Continue same dose for next 6 weeks
75 mg N=10
6 weeks treatment phase